Adverse effects: unspecified extrapyramidal symptoms · schizophrenia
CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) probably leads to lower adverse effects: unspecified extrapyramidal symptoms compared with HIGH DOSE (> 800 mg/day ‐ all medium term) (moderate certainty).
1 finding from 1 review
Adverse event: Death · schizophrenia
CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) showed no clear difference in adverse event: death compared with HIGH DOSE (> 800 mg/day ‐ all medium term) (moderate certainty).
1 finding from 1 review
Global state: needing additional medication (sedation with chloral hydrate or a barbiturate > 5 times) ‐ medium term · patients with schizophrenia
CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) showed no clear difference in global state: needing additional medication (sedation with chloral… compared with MEDIUM DOSE (401 mg/day to 800 mg/day) (low certainty).
1 finding from 1 review
Clinical response: mean score/change in mental state: mean PANSS total score (high = poor) · patients with schizophrenia
1 finding from 1 review
Leaving the study early · patients with schizophrenia
CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) showed no clear difference in leaving the study early ‐ any reason compared with MEDIUM DOSE (401 mg/day to 800 mg/day) (moderate certainty).
1 finding from 1 review
Behaviour: agitation and restlessness ‐ medium term (categorised as adverse event) · patients with schizophrenia
It is very uncertain whether CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) changes behaviour: agitation and restlessness ‐ medium term (categorised as… compared with MEDIUM DOSE (401 mg/day to 800 mg/day) (very low certainty).
1 finding from 1 review
Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia
CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) probably leads to lower adverse effects: extrapyramidal symptoms (unspecified extrapyramidal… compared with MEDIUM DOSE (401 mg/day to 800 mg/day) (moderate certainty).
1 finding from 1 review
Adverse event: Death · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global state: No clinically significant response (as defined by the original studies) · schizophrenia
CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) probably leads to higher global state: no clinically important improvement ‐ medium term compared with HIGH DOSE (> 800 mg/day ‐ all medium term) (moderate certainty).
1 finding from 1 review
Global state: needing additional medication (sedation with chloral hydrate or a barbiturate > 5 times) ‐ medium term · schizophrenia
1 finding from 1 review
Global state: clinically important change in global state needing additional medication ‐ chlorpromazine · patients with schizophrenia
It is very uncertain whether α‐FLUPENTHIXOL changes global state: clinically important change in global state needing… compared with PLACEBO or β‐FLUPENTHIXOL (very low certainty).
1 finding from 1 review
Treatment failure To discharge · newborn infants with opioid withdrawal
It is very uncertain whether phenobarbital changes treatment failure To discharge compared with chlorpromazine (very low certainty).
1 finding from 1 review
Seizures To discharge · newborn infants with opioid withdrawal
1 finding from 1 review
Neonatal or infant mortality · newborn infants with opioid withdrawal
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Neurodevelopmental disability · newborn infants with opioid withdrawal
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Length of hospital stay · newborn infants with opioid withdrawal
1 finding from 1 review
Days' pharmacological treatment · newborn infants with opioid withdrawal
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events To discharge · newborn infants with opioid withdrawal
1 finding from 1 review
Treatment failure To discharge · newborn infants with opioid withdrawal
Opioid probably leads to lower treatment failure To discharge compared with chlorpromazine (moderate certainty).
1 finding from 1 review
Seizures To discharge · newborn infants with opioid withdrawal
1 finding from 1 review